Prostate cancer treatment has improved dramatically over the last 40 years, with surgery, radiation and chemotherapy all playing a role. Still, challenges remain in diagnosing and treating the disease. For men whose cancers are not detected until they've metastasized, the chance of survival plummets to less than 28 percent.
September, designated as Prostate Cancer Awareness Month, offers an opportunity to reflect on the successes and the challenges in treating the second-leading cancer killer of men in the U.S. Our prostate cancer physicians and researchers can discuss new treatment options, current screening obstacles and research advances expected to save even more lives.
At City of Hope:
Our surgeons and oncologists use innovative treatments and technologies that produce prostate cancer survival rates higher than national averages.
Our scientists are perfecting a testosterone-targeting compound that may prevent or delay hormone-resistant prostate cancer, one of the most-difficult-to-treat types of prostate cancer.
Other researchers are working on a two-pronged attack that helps the body fight cancer. One agent inhibits the cancer’s ability to grow; the other bolsters the patient’s immune system.
Timothy Wilson, M.D.
Pauline & Martin Collins Family Chair in Urology and director of the Prostate Cancer Program.
Cy Aaron Stein, M.D., Ph.D.
Arthur & Rosalie Kaplan Chair in Medical Oncology, specializing in Urology and Urologic Oncology.